Biotech Values

[jbog]

10nis,

I was watching Adam F's Live Blog from JPM. If you go thru AF's notes he does attend the Break Out sessions but he does not mention where the following question is asked.

adam feuerstein: teva discussing why it believes any biosimilar/generic copaxone should require clinical trials prior to approval.
4:42

adam feuerstein: this Teva presentation is boring. lots of generalities, few specifics.
4:43

adam feuerstein: teva wants to target emerging markets through acquisitions
4:45

adam feuerstein: teva may generate over $30B in cash over next 5 yrs, will use the cash prudently but the ability to use cash is good. cash flow is good and will be used to fund acquisitions.
4:49

adam feuerstein: TEVA - question re: liquinamod (oral MS drug)

response: very pleased with results from first ph 3 trial. full data to be presented at AAN meeting. liquinamod demonstrated reduction in relapse rate, not gilenya like, it is in different range but it is positive and EDSS score more tysabri like. safe and oral. very compelling. product is viable and stand alone therapy.

4:50
[Comment From Guest ]
is TEVA going to get a generic Lovenox or not....they thought they would have it by the end of 2010 and nothing ever happened. Would love to know if that is asked or what indication they give over that

4:51
adam feuerstein: generic lovenox has not come up yet.

4:55
adam feuerstein: TEVA -- question -- will you get more active acquiring branded assets or companies?

response -- 50% of the pharma world today is generic. there are going to be more generic growth. opportunities are still huge relative to size. we're not going to see us growing 60% a year but 15% on average is what we think can deliver thru organic growth and acquisitions. may not be as many large acquisitions but we can do smaller, regional deals.

branded is 30% of our business and will remain for a long time. we see opportunities there, too.


5:08

Teva: we expect FDA decision on generic lovenox by end of January. We think our application is approvable but we can't guarantee that. Regardless if we get approved at end january or a bit later, we will be one of 3 or 4 players in the generic lovenox business.
5:09

Teva does not see much threat from big Pharma moving into the generic drug business.
5:17

Teva: doesn't expect the same level of European drug price cuts as was pushed thru in 2010

5:17
[Comment From Guest]
who is the forth player? There is MNTA, Lovenox, and then TEVA. That was interesting comment?

5:18
Wasn't mentioned.

5:20

Teva wrapping up. I have a meeting with NPSP so I won't be blogging again until around 3:30 pm PT.


5:20
[Comment From Guest]
4th player would probably be Sanofi, if they decided to launch an authorized generic

5:20
[Comment From Guest]
4th prob Sanofi with authorized generic
5:20
[Comment From Guest]
hospira
6:33

http://www.thestreet.com/story/10966598/1/jp-morgan-healthcare-confab-live-blog.html?kval=dontmiss